R-Tech Ueno: Announcement On Acquisition Of The Right To Develop And Commercialize DE-105 From Santen Pharmaceutical
TOKYO--(BUSINESS WIRE)--R-Tech Ueno (JASDAQ:4573)
This is to announce that R-Tech Ueno, Ltd. (Head Office: Chiyoda-ku, Tokyo, CEO and President: Yukihiko Mashima, hereinafter referred to as "R-Tech Ueno") has acquired the right to develop and commercialize DE-105 from Santen Pharmaceutical Co., Ltd. (Head Office: Kita-ku, Osaka, CEO and President: Akira Kurokawa, hereinafter referred to as "Santen"). DE-105 is a treatment targeting at persistent corneal epithelial defects that Santen has been developing.
Help employers find you! Check out all the jobs and post your resume.
This is to announce that R-Tech Ueno, Ltd. (Head Office: Chiyoda-ku, Tokyo, CEO and President: Yukihiko Mashima, hereinafter referred to as "R-Tech Ueno") has acquired the right to develop and commercialize DE-105 from Santen Pharmaceutical Co., Ltd. (Head Office: Kita-ku, Osaka, CEO and President: Akira Kurokawa, hereinafter referred to as "Santen"). DE-105 is a treatment targeting at persistent corneal epithelial defects that Santen has been developing.
Help employers find you! Check out all the jobs and post your resume.